(Q39384014)

11 September 2017

title

Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis (English)

1 reference

11 September 2017

0 references

multiple drug resistance

1 reference

6

1 reference

11 September 2017

Thomas Dick

34

0 references

Veronique Dartois

32

object named as

Veronique Dartois

1 reference

11 September 2017

Srinivasa P S Rao

1

1 reference

11 September 2017

Suresh B Lakshminarayana

2

1 reference

11 September 2017

Ravinder R Kondreddi

3

1 reference

11 September 2017

Maxime Herve

4

1 reference

11 September 2017

Luis R Camacho

5

1 reference

11 September 2017

Sarath K Kalapala

7

1 reference

11 September 2017

Jan Jiricek

8

1 reference

11 September 2017

Ng L Ma

9

1 reference

11 September 2017

Bee H Tan

10

1 reference

11 September 2017

Seow H Ng

11

1 reference

11 September 2017

Mahesh Nanjundappa

12

1 reference

11 September 2017

Sindhu Ravindran

13

1 reference

11 September 2017

Peck G Seah

14

1 reference

11 September 2017

Pamela Thayalan

15

1 reference

11 September 2017

Siao H Lim

16

1 reference

11 September 2017

Boon H Lee

17

1 reference

11 September 2017

Anne Goh

18

1 reference

11 September 2017

Whitney S Barnes

19

1 reference

11 September 2017

Zhong Chen

20

1 reference

11 September 2017

Kerstin Gagaring

21

1 reference

11 September 2017

Arnab K Chatterjee

22

1 reference

11 September 2017

Kevin Pethe

23

1 reference

11 September 2017

Kelli Kuhen

24

1 reference

11 September 2017

John Walker

25

1 reference

11 September 2017

Gu Feng

26

1 reference

11 September 2017

Sreehari Babu

27

1 reference

11 September 2017

Lijun Zhang

28

1 reference

11 September 2017

Francesca Blasco

29

1 reference

11 September 2017

David Beer

30

1 reference

11 September 2017

Margaret Weaver

31

1 reference

11 September 2017

Richard Glynne

33

1 reference

11 September 2017

Paul W Smith

35

1 reference

11 September 2017

Thierry T Diagana

36

1 reference

11 September 2017

Ujjini H Manjunatha

37

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 December 2013

1 reference

Science Translational Medicine

11 September 2017

published in

1 reference

11 September 2017

volume

5

1 reference

11 September 2017

issue

214

1 reference

11 September 2017

page(s)

214ra168

1 reference

Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Infectious disease. Approval of novel TB drug celebrated--with restraint

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Advances in the development of new tuberculosis drugs and treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Biogenesis of the mycobacterial cell wall and the site of action of ethambutol

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Discovery and characterization of a unique mycobacterial heme acquisition system

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Massive gene decay in the leprosy bacillus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Challenges and opportunities in developing novel drugs for TB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Optimisation of bioluminescent reporters for use with mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Artificial membrane assays to assess permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Cardiac ion channel safety profiling on the IonWorks Quattro automated patch clamp system

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007355

10.1126/SCITRANSLMED.3007355

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference